Literature DB >> 7767335

Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus.

M Y Samsonov1, G P Tilz, O Egorova, G Reibnegger, R M Balabanova, E L Nassonov, V A Nassonova, H Wachter, D Fuchs.   

Abstract

We investigated a possible association between markers of immune activation and disease activity in 52 patients with systemic lupus erythematosus (SLE). Serum concentrations of neopterin, beta-2-microglobulin, 55 kD-type soluble tumor necrosis factor receptor, soluble interleukin-2 receptor and soluble CD8 were compared to the Index of European Consensus Lupus Activity Measurement (ECLAM). All markers of immune activation, except sCD8, significantly correlated with ECLAM. Stepwise multiple linear regression analysis revealed erythrocyte sedimentation rate and neopterin to correlate best with ECLAM (multiple correlation coefficient = 0.74, P < 0.001). The study shows that serum neopterin concentrations are a useful independent index for disease activity in SLE. The finding of enhanced concentrations of various parameters of immune activation in patients confirm a role of the T cell and macrophage activation in the pathogenesis of SLE.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7767335     DOI： 10.1177/096120339500400107

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  12 in total

1.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

2.  Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.

Authors:  Valentin Sebastian Schäfer; Katharina Weiß; Andreas Krause; Wolfgang Andreas Schmidt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

3.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

4.  IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults.

Authors:  Sean X Leng; Xinping Tian; Amy Matteini; Huifen Li; Jennifer Hughes; Alka Jain; Jeremy D Walston; Neal S Fedarko
Journal:  Age Ageing       Date:  2011-05-17       Impact factor: 10.668

5.  In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors.

Authors:  M Jenny; M Klieber; D Zaknun; S Schroecksnadel; K Kurz; M Ledochowski; H Schennach; Dietmar Fuchs
Journal:  Inflamm Res       Date:  2010-08-26       Impact factor: 4.575

6.  Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.

Authors:  Ping Chen; Thuy Vu; Adimoolam Narayanan; Winnie Sohn; Jin Wang; Michael Boedigheimer; Andrew A Welcher; Barbara Sullivan; David A Martin; Juan Jose Perez Ruixo; Peiming Ma
Journal:  Pharm Res       Date:  2014-09-12       Impact factor: 4.200

7.  Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.

Authors:  G Stojan; H Fang; L Magder; M Petri
Journal:  Lupus       Date:  2013-06-11       Impact factor: 2.911

8.  An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma.

Authors:  Yasuhiro Tsuda; Hideo Fukui; Akira Asai; Shinya Fukunishi; Katsuhiko Miyaji; Shinya Fujiwara; Kazuhisa Teramura; Akira Fukuda; Kazuhide Higuchi
Journal:  J Clin Biochem Nutr       Date:  2012-10-12       Impact factor: 3.114

9.  Tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and their soluble receptors (sTNF-alpha-Rp55 and slL-6R) serum levels in systemic lupus erythematodes.

Authors:  E Robak; A Sysa-Jedrzejowska; T Robak; H Stepień; A Woźniacka; E Waszczykowsk
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

10.  Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.

Authors:  Michael J Boedigheimer; David A Martin; Zahir Amoura; Jorge Sánchez-Guerrero; Juanita Romero-Diaz; Alan Kivitz; Cynthia Aranow; Tak Mao Chan; Yip Boon Chong; Kit Chiu; Christine Wang; Winnie Sohn; Gregory E Arnold; Michael A Damore; Andrew A Welcher; Barbara A Sullivan; Brian L Kotzin; James B Chung
Journal:  Lupus Sci Med       Date:  2017-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.